This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Mcgill University, National Institute of Health and Medical Research, Université D'angers. Active years: 2016.
Company Filing History:
1 out of 570 
1 out of 1,853 
1 out of 55 
Years Active: 2016
Title: Raphaël Berges: Innovator in Glioma Treatment
Introduction
Raphaël Berges is a notable inventor based in Angers, France. He has made significant contributions to the field of medical research, particularly in the treatment of malignant glioma, a prevalent type of primary tumor of the central nervous system.
Latest Patents
Berges holds a patent for the "Use of a neurofilament peptide for the treatment of glioma." This invention presents a new drug aimed at treating malignant glioma. The isolated NFL-TB peptide is highly specific for glioma cells, triggering apoptosis in these cells. The invention also includes methods for detecting glioma cells in vivo and in vitro, as well as for targeting chemical compounds to these tumor cells.
Career Highlights
Throughout his career, Raphaël Berges has worked with esteemed institutions such as McGill University and Université d'Angers. His research has focused on innovative approaches to combat glioma, contributing to advancements in cancer treatment.
Collaborations
Berges has collaborated with notable colleagues, including Alan Peterson and Joël Eyer. Their combined expertise has furthered the development of effective treatments for glioma.
Conclusion
Raphaël Berges is a pioneering inventor whose work in glioma treatment showcases the potential of neurofilament peptides in medical applications. His contributions are vital in the ongoing fight against cancer, particularly in improving outcomes for patients with malignant glioma.